Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients with differential duration of treatment: an analysis of the ARISTOPHANES study

31 August 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Xiaoyan Li

Princeton (United States of America)

7 More presentations in this session

Presentation thumbnail

Men who live alone have poor anticoagulation control: results from Danish registries.

Doctor A. Nissen Bonde (Roskilde, DK)

Abstract Slides

Presentation thumbnail

Edoxaban Treatment in routiNe clinical prActice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe): 1-year follow-up according to body mass index

Professor T. Weiss (St. Polten, AT)

Presentation thumbnail

VTE-BLEED score predicts major bleeding in patients with atrial fibrillation

Professor E. Klok (Leiden, NL)

Presentation thumbnail

Optimal rivaroxaban dose in asian patients with atrial fibrillation and normal or mildly impaired renal function

Doctor E. Choi (Seoul, KR)

Presentation thumbnail

Antithrombotic challenge in the clinical dilemma of high-risk patients with atrial fibrillation: one-year result from ChiOTEAF Registry

Professor Y. Guo (Beijing, CN)

Abstract Slides

Access the full session

Session thumbnail

Poster Session 5 - Atrial fibrillation and oral anticoagulation 3

The Event

ESC Congress 2019

31 August - 4 September 2019

You may be interested in

Congress Session

Stroke prevention in clinical and subclinical atrial fibrillation

Congress Presentation

Interactive discussion and Q&A

Congress Presentation

State-of-the-art lecture on stroke and bleeding risk in atrial fibrillation: walking the tight rope

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources